Earnings Call Summary | Vaxart(VXRT.US) Q1 2024 Earnings Conference
Earnings Call Summary | Vaxart(VXRT.US) Q1 2024 Earnings Conference
The following is a summary of the Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript:
以下是Vaxart, Inc.（VXRT）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Vaxart reported Q1 2024 revenue of $2.2 million, primarily from revenue recognized under BARDA contract and non-cash royalty revenue from Inavir sales in Japan.
The company ended the first quarter with cash, cash equivalents, and investments amounting to $36.7 million.
Vaxart報告稱，2024年第一季度收入爲220萬美元，主要來自BARDA合同下確認的收入和Inavir在日本銷售的非現金特許權使用費收入。
該公司在第一季度末的現金、現金等價物和投資總額爲3670萬美元。
Business Progress:
業務進展：
Positive results from Phase 1 clinical trial evaluating Vaxart's oral pill bivalent norovirus vaccine candidate in lactating mothers.
Vaxart plans to discuss the progress of their norovirus program with the FDA in mid-2024.
Vaxart is preparing to initiate a Phase 2b trial for their COVID-19 vaccine candidate XBB as early as Q2 2024, pending additional funds and regulatory alignment.
The company is set to accelerate investment in their vaccine pipeline owing to promising preclinical data from their COVID-19 XBB construct.
A meeting with the FDA to review clinical findings and inform future regulatory pathway and clinical steps is planned for mid-2024.
Vaxart has enough vaccine material produced for the upcoming Phase 2b COVID study.
Vaxart considers their oral pill vaccine technology to be a potential tool against vaccine hesitancy.
The company continues promoting its vaccine benefits to the medical community.
評估Vaxart口服避孕藥二價諾如病毒候選疫苗的1期臨床試驗取得積極結果。
Vaxart計劃在2024年中期與美國食品藥品管理局討論其諾如病毒計劃的進展。
Vaxart正準備最早在2024年第二季度啓動其 COVID-19 候選疫苗XBB的2b期試驗，尚待額外資金和監管調整。
由於其 COVID-19 XBB 結構的臨床前數據令人鼓舞，該公司將加快對疫苗產品線的投資。
計劃於2024年中期與美國食品藥品管理局舉行會議，審查臨床發現，爲未來的監管路徑和臨床步驟提供信息。
Vaxart已經爲即將到來的2b期COVID研究生產了足夠的疫苗材料。
Vaxart認爲他們的口服藥丸疫苗技術是防止疫苗猶豫的潛在工具。
該公司繼續向醫學界宣傳其疫苗的好處。
More details: Vaxart IR
更多詳情： Vaxart 紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。